Program
volrustomig
Also written as “Volrustomig”, “MEDI5752” and “AZD9592 + Volrustomig”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Carcinoma, Renal Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 1716 open or running | phase 3since Aug 2, 2023 | Mar 28, 2018 | Jan 29, 2027phase 1 · NCT07000149 |
| Presage Biosciences | 21 open or running | early phase 1since Sep 1, 2020 | Sep 1, 2020 | Dec 2031early phase 1 · NCT04541108 |
- Named in AstraZeneca’s own pipeline as
volrustomig
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel, Daiichi Sankyo and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Mar 28, 2018.
- Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05061550 · 630 planned · United States, Belgium, Canada and more
- Nov 9, 2022Phase 1 study in Advanced Solid TumorsAstraZeneca · NCT05685472 · 6 enrolled · Japan
- Dec 7, 2022Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229 · 163 planned · United States, China, Japan and more
- Mar 2, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT05775159 · 294 enrolled · United States, China, Hong Kong and more
- Aug 2, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05984277 · 895 enrolled · United States, Argentina, Australia and more
- Sep 4, 2023Phase 3 study in Locally Advanced Cervical CancerAstraZeneca · NCT06079671 · 800 planned · United States, Brazil, Canada and more
- Oct 4, 2023Phase 3 study in MesotheliomaAstraZeneca · NCT06097728 · 863 enrolled · United States, Australia, Belgium and more
- Nov 3, 2023Phase 3 study in Locally Advanced Head and Neck Squamous Cell CarcinomaAstraZeneca · NCT06129864 · 1,145 planned · United States, Austria, Belgium and more
- Apr 3, 2024Early phase 1 study in Squamous Cell Carcinoma of Head and NeckPresage Biosciences · NCT06366451 · 17 enrolled · United States
- Jun 4, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06448754 · 194 enrolled · United States, China, France and more
- Jul 31, 2024Phase 2 study in Uterine Cervical NeoplasmsAstraZeneca · NCT06535607 · 257 planned · United States, Australia, Brazil and more
- Jan 20, 2025Phase 2 study in Colorectal NeoplasmsAstraZeneca · NCT06792695 · 82 enrolled · United States, Australia, Canada and more
- Mar 11, 2025Phase 2 study in Locally Advanced Cervical CancerAstraZeneca · NCT06943833 · 37 enrolled · Russia
- May 23, 2025Phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12AstraZeneca · NCT07000149 · 9 enrolled · Australia, South Korea
Ahead
- Jan 29, 2027Primary completion: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12AstraZeneca · NCT07000149
- May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT04379596
- Jun 30, 2027Primary completion: phase 2 study in Colorectal NeoplasmsAstraZeneca · NCT06792695
- Jul 30, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06448754
TargetBeta
“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CT…”NCIt, read by Claude
“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07000149Diabetes Mellitus, Insulin-Dependent, 12 · Australia, South Korea | 1 | Active, not recruiting | AstraZeneca | Jan 29, 2027 | 9 |
| NCT06943833Locally Advanced Cervical Cancer · Russia | 2 | Active, not recruiting | AstraZeneca | Mar 13, 2028 | 37 |
| NCT06792695Colorectal Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | AstraZeneca | Jun 30, 2027 | 82 |
| NCT06535607Uterine Cervical Neoplasms · United States, Australia, Brazil and more | 2 | Recruiting | AstraZeneca | Nov 30, 2028 | 257 |
| NCT06448754Carcinoma, Non-Small-Cell Lung · United States, China, France and more | 2 | Active, not recruiting | AstraZeneca | Jul 30, 2027 | 194 |
| NCT06366451Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Completed | Presage Biosciences | Mar 25, 2026 | 17 |
| NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma · United States, Austria, Belgium and more | 3 | Recruiting | AstraZeneca | Apr 17, 2030 | 1,145 |
| NCT06097728Mesothelioma · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Nov 16, 2028 | 863 |
| NCT06079671Locally Advanced Cervical Cancer · United States, Brazil, Canada and more | 3 | Recruiting | AstraZeneca | Nov 26, 2027 | 800 |
| NCT05984277Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Aug 17, 2026 | 895 |
| NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more | 2 | Active, not recruiting | AstraZeneca | Oct 27, 2026 | 294 |
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | AstraZeneca | Nov 30, 2027 | 163 |
| NCT05685472Advanced Solid Tumors · Japan | 1 | Completed | AstraZeneca | Aug 8, 2023 | 6 |
| NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Recruiting | AstraZeneca | May 28, 2030 | 630 |
| NCT04541108Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Active, not recruiting | Presage Biosciences | Dec 2031 | 15 |
| NCT04522323Carcinoma, Renal Cell · United States, Australia, France and more | 1 | Active, not recruiting | AstraZeneca | Sep 26, 2025 | 67 |
| NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more | 2 | Active, not recruiting | AstraZeneca | May 4, 2027 | 452 |
| NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 1 | Active, not recruiting | AstraZeneca | May 23, 2023 | 175 |
| NCT03530397Neoplasms · United States, Australia, France and more | 1 | Active, not recruiting | AstraZeneca | Jul 14, 2025 | 400 |
How it is read
Names in the registry
- “Volrustomig”, 14 entries
- “MEDI5752”, 4 entries
- “AZD9592 + Volrustomig”, 2 entries
- “volrustomig”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Uterine Cervical Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 3 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Renal Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.